Knowledge and use of biosimilars in oncology:a survey by the European Society for Medical Oncology

Background Biosimilars can potentially improve the sustainability of cancer care; however, uptake is sometimes limited by safety concerns and a lack of understanding of the concept of extrapolation. The European Society for Medical Oncology (ESMO) conducted a survey to assess the current level of knowledge, understanding and comfort of use of biosimilars among prescribers specialised in oncology.Methods A 19-question survey was developed using the SurveyMonkey online platform (https://www.surveymonkey.com/). Data collection occurred between September and October 2017 and included paper and online responses.Results Overall, 393 responses were received from prescribers. Overall, 49.0% of prescribers use biosimilars in clinical practice and most (79.2%) rate their general knowledge of biosimilars as average to very high. Potential increased risk of immunogenicity remains a significant concern of switching. Gaps in knowledge identified by the survey include biosimilar development, clinical trial design and endpoint selection, and requirements for extrapolation, which should form the focus of future educational initiatives. A substantial demand remains for further educational activities with equal preference for online and face-to-face initiatives. A higher rate of biosimilar use (56.3% vs 46.5%), knowledge of biosimilar development and trial design, and comfort with extrapolation, but a lower knowledge of European Medicines Agency definitions, was found among prescribers from Asia-Pacific versus those from Europe.Conclusion Encouraging levels of prescriber use and general knowledge of biosimilars were found, but a substantial need for further education remains. Efforts should be made worldwide to align terms, definitions and guidelines for the development and approval of biosimilars.</p

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.

Biosimilars present a necessary and timely opportunity for physicians, patients and healthcare systems. If suitably developed clinically, manufactured to the correct standards and used appropriately, they can positively impact on the financial sustainability of healthcare systems. A critical consideration regarding the introduction of biosimilars into the clinic centres on the required information concerning all the respective procedures. This position paper aims to describe the issues revolving around biosimilars that are relevant to the field of oncology, especially the prescribers. More specifically, we discuss aspects related to definition, forms of biosimilars, labelling, extrapolation, interchangeability, switching, automatic substitution, clinical standards on safety and efficacy, responsibilities among prescribers and pharmacists, potential impact on financial burden in healthcare and the current scenario and future prospects of biosimilars in Europe and the rest of the world

Preparing for the incoming wave of biosimilars in oncology

With the imminent arrival of oncology biosimilars in the therapeutic paradigm, stakeholders including a clinician, specialist nurse, patient advocate, regulator and economist provide their perspective on optimising the uptake of these new agents in the treatment of cancer. A number of key messages emerge, based on the discussion that took place during a session of the European Society for Medical Oncology's Annual Congress, ESMO Madrid 2017. First, for successful integration of biosimilars into the global healthcare paradigm, informing and educating the full scope of stakeholders, including clinicians, nurses, pharmacists and patients, is primordial. Success is dependent on providing solid evidence and ensuring all voices are heard. Second, for oncology medicines, much can be learnt from the growing experience of approved biosimilars in other disease indications, with success stories for patients, their healthcare providers and healthcare budgets alike. Finally, effective sustainability of the impact on healthcare budgets and the redirection of these savings require education and transparency

Os Momentos de transição nas rotinas de creche e de jardim de infância

Relatório do Projeto de Investigação Mestrado em Educação Pré-Escolar Versão Definitiva JaneiroO presente Relatório do Projeto de Investigação representa um estudo transversal alicerçado nas vivências ocorridas nos contextos de estágio, por outras palavras, no estágio em Creche e o no estágio em Jardim de Infância, no âmbito do Mestrado em Educação Pré-Escolar. No estudo participaram as duas Educadoras Cooperantes e os respetivos grupos de crianças. A temática em estudo consiste nos Momentos de Transição, isto é, os momentos em que as crianças transitam de uma atividade para a seguinte, e a metodologia que se considera mais apropriada ao estudo empírico posiciona-se na abordagem da investigação-ação. O método de recolha de informação baseia-se na observação participante, nas notas de campo e na análise documental, sendo complementada com inquéritos por questionário apresentados às Educadoras Cooperantes. Em jeito de complementaridade, articulam-se as experiências vivenciadas nos contextos. Este Projeto de Investigação tem como intencionalidade, refletir acerca da relação existente entre as conceções das Educadoras Cooperantes e as suas práticas pedagógicas, bem como, implementar melhorias, nas salas dos contextos de estágio, no que diz respeito à gestão dos momentos de transição. A partir desta investigação, é possível compreender que os momentos de transição são, de facto, valorizados nas conceções das Educadoras Cooperantes como momentos que requerem atenção e planeamento, porém efetivamente nem sempre a intervenção é congruente com o que defendem.This Report of the Investigation Project represents a cross-sectional study based on experiences that occured in the two internships - on nursery and on kindergarten. The two Cooperating Educators and their respective groups of children had participated in the study. The theme under study consist in the Moments of Transition, that is, the moments when the children move from one activity to the next one, and the methodology which is considered more appropriated to the empirical study is positioned in the action-research approach. The collecting information method is based on participant observation, field notes and document analysis, being complemented with questionnaire surveys presented to the Cooperating Educators. In a way of complementarity, the experiences lived in the contexts are articulated. This Investigation Project intends to reflect about the relationship between the Cooperating Educators concepts and their practices, it also intends to implement improvements in the rooms of the internship contexts, when it comes to the management of transition moments. From this investigation, it is possible to understand that transition moments are, in fact, valued in the Cooperative Educators conceptions as moments that require attention and planning, however, the intervention is not always consistent with what they defend

Global cancer control : responding to the growing burden, rising costs and inequalities in access

The cancer burden is rising globally, exerting significant strain on populations and health systems at all income levels. In May 2017, world governments made a commitment to further invest in cancer control as a public health priority, passing the World Health Assembly Resolution 70.12 on cancer prevention and control within an integrated approach. In this manuscript, the 2016 European Society for Medical Oncology Leadership Generation Programme participants propose a strategic framework that is in line with the 2017 WHO Cancer Resolution and consistent with the principle of universal health coverage, which ensures access to optimal cancer care for all people because health is a basic human right. The time for action is now to reduce barriers and provide the highest possible quality cancer care to everyone regardless of circumstance, precondition or geographic location. The national actions and the policy recommendations in this paper set forth the vision of its authors for the future of global cancer control at the national level, where the WHO Cancer Resolution must be implemented if we are to reduce the cancer burden, avoid unnecessary suffering and save as many lives as possible

Not Available

Not AvailableNot AvailableNot Availabl

Current models, challenges and best practices for work conducted between European academic cooperative groups and industry

BACKGROUND The academia-industry interface is important, and, despite challenges that inevitably occur, bears the potential for positive synergies to emerge. Perceived barriers to wider collaboration in academia-industry oncology research in Europe need to be addressed, current academic cooperative group and industry models for collaboration need to be discussed, and a common terminology to facilitate understanding of both sectors' concerns needs to be established with an eye towards improving academia-industry partnerships on clinical trials for the benefit of patients with cancer. METHODOLOGY CAREFOR (Clinical Academic Cancer Research Forum), a multi-stakeholder platform formed to improve the direction for academic clinical trials in the field of oncology in Europe, formed the CAREFOR-Industry Working Group comprised of experienced professionals from European academic cooperative groups joined by industry representatives selected based on their activities in the area of medical oncology. They jointly discussed academic cooperative groups, clinical trials conducted between academic cooperative groups and industry, examples of successful collaborative models, common legal negotiation points in clinical trial contracts, data access, and principles of interaction. RESULTS Four principles of interaction between the academia and industry are proposed: (1) clarify the roles and responsibilities of all partners involved in the study, (2) involve legal teams from an early stage; (3) acknowledge that data is an important output of the study, (4) agree on the intent of the trial prior to its start. CONCLUSIONS The CAREFOR-Industry Working Group describes current models, challenges, and effective strategies for academia-industry research in Europe with an eye towards improving academia-industry partnerships on clinical trials for patients with cancer. Current perceived challenges are explained, and future opportunities/recommendations for improvement are described for the areas of most significant impact. Challenges are addressed from both the academic and industry perspectives, and principles of interaction for the optimal alignment between academia and industry in selected areas are proposed

Shortages of inexpensive essential medicines

This issue includes articles about reading among elementary school children, a new freshman coach (Pat Malone), and the return of the Dayton Boosters\u27 June Jamboree. Also included are happenings from around campus, sporting news, and alumni notes.https://ecommons.udayton.edu/dayton_mag/1047/thumbnail.jp

Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology

Biosimilars; Oncologia; PrescriptorsBiosimilares; Oncología; PrescriptoresBiosimilars; Oncology; PrescribersBackground: Biosimilars can potentially improve the sustainability of cancer care; however, uptake is sometimes limited by safety concerns and a lack of understanding of the concept of extrapolation. The European Society for Medical Oncology (ESMO) conducted a survey to assess the current level of knowledge, understanding and comfort of use of biosimilars among prescribers specialised in oncology. Methods: A 19-question survey was developed using the SurveyMonkey online platform (https://www.surveymonkey.com/). Data collection occurred between September and October 2017 and included paper and online responses. Results: Overall, 393 responses were received from prescribers. Overall, 49.0% of prescribers use biosimilars in clinical practice and most (79.2%) rate their general knowledge of biosimilars as average to very high. Potential increased risk of immunogenicity remains a significant concern of switching. Gaps in knowledge identified by the survey include biosimilar development, clinical trial design and endpoint selection, and requirements for extrapolation, which should form the focus of future educational initiatives. A substantial demand remains for further educational activities with equal preference for online and face-to-face initiatives. A higher rate of biosimilar use (56.3% vs 46.5%), knowledge of biosimilar development and trial design, and comfort with extrapolation, but a lower knowledge of European Medicines Agency definitions, was found among prescribers from Asia-Pacific versus those from Europe. Conclusion: Encouraging levels of prescriber use and general knowledge of biosimilars were found, but a substantial need for further education remains. Efforts should be made worldwide to align terms, definitions and guidelines for the development and approval of biosimilars